ZBIO — Zenas BioPharma Share News
0.000.00%
Last trade - 00:00- $1.66bn
- $1.40bn
- $10.00m
Brief: Innocare Pharma Announces Achievement Of Primary Endpoint In Phase 2B Study Of Orelabrutinib,
Brief: Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial Of Obexelimab In Relapsing Multiple Sclerosis
Zenas BioPharma hits record high as brokerages raise PT
Brief: Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing
U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy
U.S. STOCKS ON THE MOVE-United Rentals, Dell, Datadog
U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66
U.S. STOCKS ON THE MOVE-Intel, Schlumberger, FedEx
Zenas rises on licensing deal for autoimmune drug potentially worth over $2 billion
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
Brief: InnoCare, Zenas sign global licensing pact worth over $2 bln
Brief: Innocare Says Unit Signs License Agreement With Zenas Biopharma
Brief: Zenas Biopharma And Royalty Pharma Enter Into Obexelimab Funding Agreement For Up To $300 Million
Brief: Zenas Biopharma announces inducement grant under Nasdaq listing rule
Brief: Zenas Biopharma Reports First Quarter 2025 Financial Results
Brief: Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives
Brief: Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives
Brief: Enavate Sciences Reports 9.0% Stake In Zenas Biopharma
Zenas BioPharma shares rise nearly 8% in market debut (updated)